Solid Tumor Clinical Trials in Santa Monica, California

7 studies are recruiting for solid tumor in Santa Monica, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

   The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarcoma Oncology Center, Santa Monica, California

   Locations

   13 in total

   Run by

   ImmunoGenesis

   See if you can join NCT06014502 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarcoma Oncology Center, Santa Monica, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. A Study of ASP3082 in Adults With Advanced Solid Tumors

   This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica Hematology Oncology, Santa Monica, California

   Locations

   66 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT05382559 on ClinicalTrials.gov

4. Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

   This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary an…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   CBCC Global Research Site 008, Santa Monica, California

   Locations

   9 in total

   Run by

   Alyssum Therapeutics

   See if you can join NCT06234098 on ClinicalTrials.gov

5. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica Hematology Oncology, Santa Monica, California

   Locations

   20 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

6. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

   The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA, Santa Monica, California

   Locations

   27 in total

   Run by

   Oxford BioTherapeutics Ltd

   See if you can join NCT04064359 on ClinicalTrials.gov

7. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Saint John's Health Center, Santa Monica, California

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov